Continue Reading
Full article on Bloomberg
Eli Lilly-Backed Aktis Oncology Gets $317.7 Million in US IPO
Market Intelligence Analysis
AI-Powered
Why This Matters
Aktis Oncology, a biotech company backed by Eli Lilly, raised $317.7 million in its US IPO, pricing at the top of its marketed range.
Market Impact
Market impact analysis based on bullish sentiment with 80% confidence.
Sentiment
Bullish
AI Confidence
80%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.
Original article published by
Bloomberg
on January 9, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.